BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1239 related articles for article (PubMed ID: 32108133)

  • 1. Synaptotagmin 12 (SYT12) Gene Expression Promotes Cell Proliferation and Progression of Lung Adenocarcinoma and Involves the Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
    Liu K; Luo J; Shao C; Ren Z; Sun S; Zhu Y; Zhou H; Jiang Z; Li X; Gu W; Xu Y; Qiang Y; Ren B; Xu L; Wu H; Shen Y
    Med Sci Monit; 2020 Feb; 26():e920351. PubMed ID: 32108133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyanidin-3-glucoside suppresses the progression of lung adenocarcinoma by downregulating TP53I3 and inhibiting PI3K/AKT/mTOR pathway.
    Chen X; Zhang W; Xu X
    World J Surg Oncol; 2021 Aug; 19(1):232. PubMed ID: 34362378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SLC39A5 promotes lung adenocarcinoma cell proliferation by activating PI3K/AKT signaling.
    Liu Z; Hu Z; Cai X; Liu S
    Pathol Res Pract; 2021 Aug; 224():153541. PubMed ID: 34252710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TM6SF1 suppresses the progression of lung adenocarcinoma and M2 macrophage polarization by inactivating the PI3K/AKT/mtor pathway.
    Huang S; Zhao H; Lou X; Chen D; Shi C; Ren Z
    Biochem Biophys Res Commun; 2024 Jul; 718():149983. PubMed ID: 38718735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway.
    Wei C; Dong X; Lu H; Tong F; Chen L; Zhang R; Dong J; Hu Y; Wu G; Dong X
    J Exp Clin Cancer Res; 2019 Feb; 38(1):95. PubMed ID: 30791942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Junctional adhesion molecule-like protein as a novel target for kaempferol to ameliorate lung adenocarcinoma.
    Wu Q; Wang YB; Che XW; Wang H; Wang W
    J Integr Med; 2023 May; 21(3):268-276. PubMed ID: 37069006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UHMK1 promotes lung adenocarcinoma oncogenesis by regulating the PI3K/AKT/mTOR signaling pathway.
    Li Y; Wang S; Jin K; Jin W; Si L; Zhang H; Tian H
    Thorac Cancer; 2023 Apr; 14(12):1077-1088. PubMed ID: 36919755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agmatinase promotes the lung adenocarcinoma tumorigenesis by activating the NO-MAPKs-PI3K/Akt pathway.
    Zhu HE; Yin JY; Chen DX; He S; Chen H
    Cell Death Dis; 2019 Nov; 10(11):854. PubMed ID: 31699997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SLITRK6 promotes the progression of lung adenocarcinoma by regulating PI3K/AKT/mTOR signaling and Warburg effect.
    Yu F; Zhao X; Li M; Meng M
    Apoptosis; 2023 Aug; 28(7-8):1216-1225. PubMed ID: 37219677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mex3a interacts with LAMA2 to promote lung adenocarcinoma metastasis via PI3K/AKT pathway.
    Liang J; Li H; Han J; Jiang J; Wang J; Li Y; Feng Z; Zhao R; Sun Z; Lv B; Tian H
    Cell Death Dis; 2020 Aug; 11(8):614. PubMed ID: 32792503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-218 regulates the epithelial-to-mesenchymal transition and the PI3K/Akt signaling pathway to suppress lung adenocarcinoma progression by directly targeting BMI-1.
    Xu L; Sun HB; Xu ZN; Han XL; Yin YY; Zheng Y; Zhao Y; Wang ZX
    Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7978-7988. PubMed ID: 31599423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA (let-7b-5p)-targeted DARS2 regulates lung adenocarcinoma growth by PI3K/AKT signaling pathway.
    Xu Y; Chen X
    Oncol Res; 2024; 32(3):517-528. PubMed ID: 38361754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of CENPM facilitates lung adenocarcinoma progression via PI3K/AKT/mTOR signaling pathway.
    Liu C; Wang Y; Dao Y; Wang S; Hou F; Yang Z; Liu P; Lv J; Lv L; Li G; Zhou Y; Deng Z
    Acta Biochim Biophys Sin (Shanghai); 2022 Jan; 54(1):99-112. PubMed ID: 35130633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Schlafen 5 Inhibits Proliferation and Promotes Apoptosis in Lung Adenocarcinoma via the PTEN/PI3K/AKT/mTOR Pathway.
    Gu X; Zhou L; Chen L; Pan H; Zhao R; Guang W; Wan G; Zhang P; Liu D; Deng LL; Zhao W; Lu C
    Biomed Res Int; 2021; 2021():6628682. PubMed ID: 33860045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-381 inhibits lung adenocarcinoma cell biological progression by directly targeting LMO3 through regulation of the PI3K/Akt signaling pathway and epithelial-to-mesenchymal transition.
    Xuan YW; Liao M; Zhai WL; Peng LJ; Tang Y
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8411-8421. PubMed ID: 31646571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD73 (NT5E) Promotes the Proliferation and Metastasis of Lung Adenocarcinoma through the EGFR/AKT/mTOR Pathway.
    Zhang H; Cao Y; Tang J; Wang R
    Biomed Res Int; 2022; 2022():9944847. PubMed ID: 35813221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FHL2 promotes the aggressiveness of lung adenocarcinoma by inhibiting autophagy via activation of the PI3K/AKT/mTOR pathway.
    Wang S; Liu B; Su Y; Wang N; Dong P; Xu X; Huang L; Li S; Gu J; Qiu Y; Deng J; Lin Z; Zhou Y
    Thorac Cancer; 2024 Mar; 15(8):630-641. PubMed ID: 38323374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis.
    Lou Y; Xu J; Zhang Y; Zhang W; Zhang X; Gu P; Zhong H; Wang H; Lu J; Han B
    Cell Death Dis; 2021 Feb; 12(2):170. PubMed ID: 33568630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of FYN suppresses the epithelial-to-mesenchymal transition through down-regulating PI3K/AKT pathway in lung adenocarcinoma.
    Xue F; Jia Y; Zhao J
    Surg Oncol; 2020 Jun; 33():108-117. PubMed ID: 32561075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KIF18B as a regulator in microtubule movement accelerates tumor progression and triggers poor outcome in lung adenocarcinoma.
    Ji Z; Pan X; Shang Y; Ni DT; Wu FL
    Tissue Cell; 2019 Dec; 61():44-50. PubMed ID: 31759406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.